Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Abbott Laboratories (ABT) - free report >>
Bristol Myers Squibb Company (BMY) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Laboratories (ABT) - free report >>
Bristol Myers Squibb Company (BMY) - free report >>
Image: Bigstock
Novo Nordisk (NVO) Reports Positive Trial Results on Victoza
Novo Nordisk (NVO - Free Report) announced results from the LEADER trial on Victoza at the American Diabetes Association's 76th Scientific Sessions.
Results were also published in the New England Journal of Medicine.
The trial is evaluating the long-term effects of Victoza, in comparison to placebo, both in addition to the standard of care, in people with type 2 diabetes at high risk of major cardiovascular (CV) events.
Results from the multicenter, international, randomized, double-blinded, placebo-controlled trial showed that Victoza significantly reduced the risk of the composite primary endpoint of CV death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13%, compared to placebo, when added to the standard of care in adults with type II diabetes at high CV risk.
Results also showed that treatment with Victoza resulted in a 22% reduction in cardiovascular death, compared to placebo.
This means that Victoza can improve outcomes beyond glucose reduction and weight loss in reducing cardiovascular complications and death in people with type II diabetes.
NOVO-NORDISK AS Price
NOVO-NORDISK AS Price | NOVO-NORDISK AS Quote
We note that Victoza is indicated in Europe for the treatment of adults with type II diabetes to achieve glycemic control as monotherapy, when metformin is considered inappropriate, and in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycemic control. The drug is also approved in the U.S. as an adjunct to diet and exercise to improve blood glucose control in adults with type II diabetes.
These results bode well for Victoza. We note that Novo Nordisk has a strong presence in the diabetes care market, supported by one of the broadest diabetes portfolios in the industry comprising drugs like Victoza, Levemir and modern insulins.
Novo Nordisk carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector are Pfizer, Inc. (PFE - Free Report) , Bristol-Myers Squibb Co. (BMY - Free Report) and Abbott Laboratories (ABT - Free Report) . While Pfizer and Bristol-Myers sport a Zacks Rank #1 (Strong Buy), Abbott Labs is a Zacks Rank #2 (Buy) stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>